Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute

Lung Cancer. 2018 Dec:126:210-216. doi: 10.1016/j.lungcan.2017.11.012. Epub 2017 Nov 17.

Authors

Robert D Schouten¹, Mirte Muller¹, Cornedine J de Gooijer¹, Paul Baas², Michel van den Heuvel¹

Affiliations

¹ Department of Thoracic Oncology, Netherlands Cancer Institute (NKI), Amsterdam.
² Department of Thoracic Oncology, Netherlands Cancer Institute (NKI), Amsterdam. Electronic address: p.baas@nki.nl.

PMID: 29179916
DOI: 10.1016/j.lungcan.2017.11.012

No abstract available

Keywords: Efficacy; Nivolumab; Non-small cell lung cancer; Real life; Safety.

MeSH terms

Adult
Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Hypothyroidism / chemically induced
Kaplan-Meier Estimate
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Middle Aged
Netherlands
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Tertiary Care Centers*

Substances

Antineoplastic Agents, Immunological
Nivolumab